Actively Recruiting
Biobanking for Biomarkers in Respiratory Disease, Allergic Diseases, and Mast Cell Disorders
Led by University Hospital, Toulouse · Updated on 2024-05-01
3200
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting biological samples and clinical data from adults with allergic diseases, asthma, or mast cell disorders to create a biobank. This resource aims to support future research by identifying new diagnostic, prognostic, and predictive biomarkers related to these conditions. The study is observational and involves patients suspected of or diagnosed with these diseases. Participants provide samples and health information that will be pseudonymised to protect privacy. The samples and data will be stored securely and may be used by the Toulouse University Hospital research teams or shared with national and international collaborators under strict legal agreements. This collection supports exploratory and predictive studies in allergy and mast cell disorders. During the study, participants will provide samples and relevant clinical data. Researchers will use these to explore various allergy markers, study biological mechanisms, and track changes in biomarkers over time. The main outcome is the establishment and use of this biobank over 15 years to facilitate ongoing research in respiratory and allergic diseases as well as mast cell disorders.
CONDITIONS
Brief Title
Biobanking for Biomarkers In Respiratory Disease, Allergic Diseases and/or Mast Cell Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a positive prick test or specific IgE regardless of the allergen
- Patients suspected of allergic pathology needing a prick test, specific IgE, or food/drug reintroduction test
- Patients with systemic or cutaneous mastocytosis as per international classification
- Patients with mast cell activation syndrome as per international classification
- Patients with familial hyper-alpha tryptasemia linked to TPSAB1 gene variation
- Patients with asthma of any severity
- People affiliated or beneficiaries of a social security scheme
- Patients able to understand study information and provide written consent in French, without legal restrictions
You will not qualify if you...
- Patients under legal protection, guardianship, or curatorship
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 years
Participants provide biological samples and clinical data for biobanking to support diagnostic and exploratory research.
Visits as needed for sample collection and clinical data sharing
Duration - Up to 15 years
Participants' biomarker data and samples are observed over time to support research on allergic diseases, asthma, and mast cell disorders.
Periodic visits depending on research needs
Trial Site Locations
Total: 1 location
1
Laurent GUILLEMINAULT
Toulouse, France, 31059
Actively Recruiting
Research Team
L
Laurent GUILLEMINAULT, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here